Patents
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
10/2006
10/18/2006EP1711527A2 Hla-dr-specific antibodies, compositions and methods
10/18/2006EP1711525A2 Neoplasm-specific polypeptides and their uses
10/18/2006EP1711509A2 Inhibition of bright function as a treatment for excessive immunoglobulin production
10/18/2006EP1711208A2 Conjugates of amyloid proteins as vaccines for amyloid-related diseases
10/18/2006EP1711207A2 Interferon alpha antibodies and their uses
10/18/2006EP1389236B1 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
10/18/2006EP1337636B1 Soluble zcytor 11 cytokine receptors
10/18/2006EP1242460B1 Immobilisation of proteins using a polypeptide segment
10/18/2006EP1208196B1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
10/18/2006EP1165778B1 Uses of casb618 polynucleotides and polypeptides
10/18/2006EP1141286B1 Cytokine receptor chain
10/18/2006EP1131434B1 Apoptosis-inducing factor
10/18/2006EP1127126B1 G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof
10/18/2006EP1104479B1 Method for recovering proteins from the interstitial fluid of plant tissues
10/18/2006EP1071710B1 Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
10/18/2006EP1050584B1 Recombinant lysophosphatidic acid phosphatase
10/18/2006EP1042468B1 Low-voltage activated calcium channel compositions and methods
10/18/2006EP1019500B1 Ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
10/18/2006EP1004667B1 Cell cycle-regulating proteins
10/18/2006EP0944649B1 METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS
10/18/2006EP0927252B1 Antibodies against interferon alpha/beta receptor
10/18/2006EP0914156B1 Passively administered antibody that enhances feed conversion efficiency
10/18/2006EP0797664B1 Use of a human interleukin-11 receptor
10/18/2006EP0778849B1 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
10/18/2006CN1849400A Polynucleotides and polypeptides of the erythropoietin gene
10/18/2006CN1849395A HLA-a24 binding cancer antigen peptide derived from ribin
10/18/2006CN1849389A Methods for producing recombinant proteins
10/18/2006CN1849339A 治疗性结合分子 Therapeutic binding molecules
10/18/2006CN1849338A Antibodies against interleukin-1 receptor and uses thereof
10/18/2006CN1849337A Compositions and methods for treating cancer using IGSF9 and LIV-1
10/18/2006CN1849334A Lawsonia intracellularis subunit vaccine
10/18/2006CN1849144A Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B
10/18/2006CN1849139A Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
10/18/2006CN1849138A Human anti-NGF neutralizing antibodies as selective ngf pathway inhibitors
10/18/2006CN1849137A Special reagent for diagnosing and treating disease based on VEFG,HER-2,PSA protein isomer
10/18/2006CN1849136A Cancerous disease modifying antibodies
10/18/2006CN1849135A Methods for treating interleukin-6-related diseases
10/18/2006CN1847397A EHEC 0157 shiga-like toxin IIA resisting subunit monoclonal antibody 5F3 light and heavy chain variable region gene and its application
10/18/2006CN1280414C Human antibody heavy chain and light chain variable region gene against SARS-Cov S antigen and polypeptide and use thereof
10/17/2006USRE39350 RNA binding protein and binding site useful for expression of recombinant molecules
10/17/2006US7122656 MyD88S allows activation of JNK and AP-1, whereas the NF- kappa B pathway is completely blocked; used to obtain immunosuppression (e.g., in the case of transplantation); modulation of the expression of MyD88S can regulate the cellular responses to LPS and other immunological stimuli
10/17/2006US7122654 Hybrid; adjust vascular system permeability
10/17/2006US7122652 Isolated polynucleotide encoding a variant human pregnane X receptor (hPXR) polypeptide or fragment; detection and genotyping of hPXR alleles in humans, homozygous as well as heterozygous, alleles of the hPXR gene
10/17/2006US7122646 Multivalent and multispecific binding proteins, their manufacture and use
10/17/2006US7122641 Methods for purifying protein
10/17/2006US7122639 Chemokine alpha-2 antibodies
10/17/2006US7122638 Hybridomas cell lines; viricides
10/17/2006US7122637 Polypeptide variants with altered effector function
10/17/2006US7122636 Antibody fragment-polymer conjugates and uses of same
10/17/2006US7122635 Method and composition for angiogenesis inhibition
10/17/2006US7122630 Proteins in cell cycle regulation; cell cycle protein binds to SYK kinase
10/17/2006US7122629 For forensic analyses, chromosome tissue/cell/organelle-specific markers, production of expression vectors, screening and diagnosis assays
10/17/2006US7122622 Somatostatin analogue as peptide and chelating group covalently linked to N-terminal free amino group of peptide, wherein analogue carries 1-naphthylalanine or 3-benzothienylalanine residue in 3-position; diagnosis
10/17/2006US7122572 For use in Hydrogen Bonding Liquid Chromatography, environmental remediation by removal of undesired ions or neutral molecules, removal of phosphate for kidney dialysis, drug delivery, separation
10/17/2006US7122524 Stimulating nerve growth, administering glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide; due to ischemic, traumatic or toxic origin
10/17/2006US7122374 For immunotherapy for the treatment of diseases, e.g., neurodegenerative diseases
10/17/2006US7122373 Human genes and gene expression products V
10/17/2006US7122372 Peptide useful in immunomodulation
10/17/2006US7122363 Comprises nucleotide sequences coding cyclic nucleotide phosphodiesterases for treatment of cardiovascular, depressive and vascular disorders; cardiotonic agents; antidepressants; antihypertensives; antithrombotics
10/17/2006US7122362 For diagnosing, treating, or preventing disorders associated with aberrant expression of human phosphodiesterases
10/17/2006US7122361 Compositions employing a novel human kinase
10/17/2006US7122360 Polypeptides, polynucleotides and uses thereof
10/17/2006US7122351 Dimerized PDGF-D and materials and methods for producing it
10/17/2006US7122339 Method for generating diversity
10/17/2006US7122336 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
10/17/2006US7122327 Utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state, and most particularly to specific biopolymer markers whose up-regulation, down-regulation, or relative presence in disease vs. normal states
10/17/2006US7122324 Vitro methods for determining in vivo thrombotic events
10/17/2006US7122322 Endometriosis-specific secretory protein
10/17/2006US7122320 Method for detecting acid-resistant microorganisms in the stool
10/17/2006US7122302 Method for determining early HCV seroconversion
10/17/2006US7122197 Compounds from Moraxella catarrhalis
10/17/2006US7122196 Compounds and methods for diagnosis of tuberculosis
10/17/2006US7122194 Mixture of polypeptide with carrier
10/17/2006US7122193 Comprising peptide analogues which have a half-life which is clearly superior to that of natural proteins or that of synthetic peptides which are or are not derived from these natural proteins
10/17/2006US7122187 Treating autoimmune diseases with humanized anti-CD40L antibody
10/17/2006US7122186 For use in diagnostic, therapeutic, and industrial contexts
10/17/2006US7122185 Nucleic acids; prevent humans lymphocyte virus infection; genetic engineering; transformation cells
10/17/2006US7122184 Monoclonal antibody for use in prevention of fungal infections
10/17/2006US7122183 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
10/17/2006CA2342141C Method for detection of legionella bacteria employing purified antigen-specific antibodies
10/17/2006CA2195557C Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
10/17/2006CA2177179C Antagonists to chaperonin 10
10/17/2006CA2150497C Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
10/12/2006WO2006108167A1 Bioactive stents for type ii diabetics and methods for use thereof
10/12/2006WO2006107708A1 Treatment of disease caused by excess free hemoglobin
10/12/2006WO2006107617A2 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
10/12/2006WO2006107124A1 Immunoglobulin fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
10/12/2006WO2006106959A1 Anti-cd-20 monoclonal antibody
10/12/2006WO2006106957A1 Monoclonal antibody specifically recognizing modification site after translation of p53 and kit for assaying modification site containing the same
10/12/2006WO2006106950A1 Novel anti-heparan sulfate antibody, method for detection of heparan sulfate, and kit for detection of heparan sulfate
10/12/2006WO2006106912A1 Cancer-associated antigen analog peptide and utilization of the same
10/12/2006WO2006106905A1 Process for production of polypeptide by regulation of assembly
10/12/2006WO2006106903A1 sc(Fv)2 STRUCTURAL ISOMERS
10/12/2006WO2006106823A1 Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
10/12/2006WO2006106341A2 Sheep primers
10/12/2006WO2006106339A1 Pig primers
10/12/2006WO2006106336A2 Rat primers
10/12/2006WO2006106331A2 Mouse primers
10/12/2006WO2006106323A1 Method for obtaining antibodies
10/12/2006WO2006087637A3 Anti her2/neu antibody